Objective:

To address the urgent issue of contaminated cough medicines containing diethylene glycol (DEG) and ethylene glycol (EG) and the need for coordinated action in the medical supply chain.

Approach:

• WHO's Call to Action: WHO has urged stakeholders to detect and remove substandard products, enhance market surveillance, and enforce regulations.
• Role of Medicine Makers: Pharmaceutical manufacturers must ensure quality by sourcing from qualified suppliers and conducting thorough testing.
• Supplier Responsibilities: Suppliers need to verify the authenticity of products and maintain accurate records to prevent falsification.
• Historical Context: The IPEC Federation and WHO have been involved in supply chain security since incidents of DEG contamination emerged in the 1990s.

Key Findings:

• Recent incidents of DEG contamination have led to calls for updated guidelines and stricter supply chain management.
• Historical cases of DEG poisoning highlight the ongoing risks associated with contaminated pharmaceutical products.
• The IPEC Federation emphasizes the need for robust quality control and traceability in the supply chain.

Interpretation:

Limitations:

• The article does not provide specific data on the current incidence rates of DEG contamination.
• No detailed analysis of the effectiveness of past guidelines is included.

Conclusion:

The IPEC Federation plans to update its position paper to reinforce the importance of safe management of excipient supply chains.

Sources:

• World Health Organization
• IPEC Federation